Related Experiment Video

Updated: Jun 15, 2026

The Pilocarpine Model of Temporal Lobe Epilepsy and EEG Monitoring Using Radiotelemetry System in Mice
10:08

The Pilocarpine Model of Temporal Lobe Epilepsy and EEG Monitoring Using Radiotelemetry System in Mice

Published on: February 27, 2018

Mitochondrial base excision repair pathway failed to respond to status epilepticus induced by pilocarpine

Youting Lin1, Jingjing Xu, Lili Cao

  • 1Department of Neurology, Qilu Hospital, Shandong University, 44#, Wenhua Xi Road, Jinan 250012, PR China.

Neuroscience Letters
|March 9, 2010
PubMed

Insights

Mitochondrial DNA repair enzymes decreased during seizures, suggesting a failure in the base excision repair pathway. This impairment may worsen mitochondrial damage and deficiency in epileptic seizures.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Oxidative damage to mitochondrial DNA (mtDNA) is linked to mitochondrial dysfunction in epileptic seizures.
  • The mitochondrial base excision repair (mtBER) pathway is crucial for maintaining mtDNA integrity.

Purpose of the Study:

  • To investigate the response of the mtBER pathway in a rat model of pilocarpine-induced status epilepticus (SE).
  • To determine the expression levels of key mtBER enzymes (OGG1, polgamma, APE1) following SE.

Main Methods:

  • Pilocarpine was used to induce SE in male Wistar rats.
  • Hippocampal tissues were analyzed for mRNA and mitochondrial protein levels of OGG1, polgamma, and APE1 at 3, 9, and 25 hours post-SE onset.

Main Results:

  • Expression of 8-oxoguanine DNA glycosylase (OGG1) and polymerase gamma (polgamma) decreased at both mRNA and protein levels post-SE.
  • While APE1 mRNA levels were maintained, its mitochondrial protein levels decreased at 3 and 9 hours, recovering by 25 hours.
  • The mtBER pathway demonstrated a failure to respond adequately to pilocarpine-induced SE.

Conclusions:

  • The study suggests a failure of the mtBER pathway in response to SE, potentially due to impaired mitochondrial import of repair enzymes.
  • Down-regulation of mtBER enzymes may exacerbate mtDNA damage and mitochondrial deficiency in epileptic seizures.
  • Targeting mtBER pathway dysfunction could be a therapeutic strategy for managing seizures.

More Related Videos

Assessment of Memory Function in Pilocarpine-induced Epileptic Mice13:34

Assessment of Memory Function in Pilocarpine-induced Epileptic Mice

Published on: June 4, 2020

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...